Skip to main content
SpringerLink
Log in

Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer

  • Immuno-oncology (RM Bukowski and JH Finke, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

T-cell immunoglobulin and ITIM domain (TIGIT) is a next-generation inhibitory receptor with multiple antibodies under exploration in cancer therapy. Here, we review the available data from the early trials and overview upcoming clinical trials on anti-TIGIT antibodies.

Recent Findings

There is a promising activity of anti-TIGIT, particularly in combination with anti-PD-1/PD-L1 in non-small cell lung cancer (NSCLC) with already phase 3 trials currently ongoing to confirm these early findings.

Summary

Numerous anti-TIGIT antibodies are in clinical trials currently, and others are in preclinical development. Therefore, more data are expected in the next few years regarding the efficacy of this new checkpoint inhibitor in multiple solid and hematologic malignancies. However, preliminary data are promising, and anti-TIGIT treatment seems to confer more favorable responses when combined with anti-PD-1/anti-PD-L1 compared to either agent alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Anderson AC, Joller N, Kuchroo VK. L1 Anderson, A. C., Joller, N. and Kuchroo, V. K. (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity, NIH Public Access 44, 989–1004.ag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specia. Immunity. 2016;44:989–1004.

    Article  CAS  Google Scholar 

  2. Levin SD, Taft DW, Brandt CS, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011;41:902–15.

    Article  CAS  Google Scholar 

  3. Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106:17858–63.

    Article  CAS  Google Scholar 

  4. • Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57. (One of the first reports on TIGIT immunosuppressive role.)

    Article  CAS  Google Scholar 

  5. Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol. 2009;39:695–703.

    Article  CAS  Google Scholar 

  6. Liu S, Zhang H, Li M, Hu D, Li C, Ge B, Jin B, Fan Z. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20:456–64.

    Article  CAS  Google Scholar 

  7. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, Sharpe AH, Kuchroo VK. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186:1338–42.

    Article  CAS  Google Scholar 

  8. Josefsson SE, Huse K, Kolstad A, et al. T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling. Clin Cancer Res. 2018;24:870–81.

    Article  CAS  Google Scholar 

  9. Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276:112–20.

    Article  CAS  Google Scholar 

  10. Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923–37.

    Article  CAS  Google Scholar 

  11. Chauvin J-M, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125:2046–58.

    Article  Google Scholar 

  12. • Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38:9503–9503. (Key studies on anti-TIGIT antibodies in the treatment of lung cancer.)

    Article  Google Scholar 

  13. • Cho BC, Rodriguez-Abreu D, Hussein M, et al (2021) LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC. Ann Oncol 32:S1428. (Key studies on anti-TIGIT antibodies in the treatment of lung cancer.)

  14. • Niu J, Maurice-Dror C, Lee DH, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.11.002. (Key studies on anti-TIGIT antibodies in the treatment of lung cancer.)

    Article  Google Scholar 

  15. Van den Mooter TFA, Migeotte A, Jungels C, et al (2021) Abstract CT118: Preliminary data from phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers. In: Clin. Trials. American Association for Cancer Research, pp CT118–CT118

  16. Piovesan D, Lopez A, Schweickert P, et al. 258 AB308 is an anti-TIGIT antibody that enhances immune activation and anti-tumor immunity alone and in combination with other I-O therapeutic agents. J Immunother Cancer. 2021;9:A280–A280.

    Article  Google Scholar 

  17. Chaudhry A, Johnson M, Colburn D, Gilbert H, Garofalo A, Paoloni M, Krishnan K. 1419TiP ARC-7: a phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC). Ann Oncol. 2020;31:S897.

    Article  Google Scholar 

  18. Frentzas S, Meniawy T, Kao SC-H, Wang R, Zuo Y, Zheng H, Tan W. AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors. J Clin Oncol. 2021;39:2583–2583.

    Article  Google Scholar 

  19. Xu R, Kim S-B, Tougeron D, Zuo Y, Yang H, Zhang J, Shi J, Van Cutsem E. AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed de. J Clin Oncol. 2021;39:TPS4150–TPS4150.

    Article  Google Scholar 

  20. Wu L, Wang P-H, Hsiao S-Y, et al. AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer. J Clin Oncol. 2021;39:TPS5595–TPS5595.

    Article  Google Scholar 

  21. Socinski MA, Spira AI, Paz-Ares LG, et al. AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung c. J Clin Oncol. 2021;39:TPS9128–TPS9128.

    Article  Google Scholar 

  22. Mettu NB, Ulahannan S V., Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S (2021) A phase 1a/b open‑label, dose‑escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2780.2021

  23. Dumbrava E, Sharma M, Fleming G, et al (2021) COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab - preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors. In: SITC Annu. Meet. p Abstract 478

  24. Garralda E, Sanborn RE, Minchom AR, et al. SGNTGT-001: a phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress). J Clin Oncol. 2021;39:TPS2657–TPS2657.

    Article  Google Scholar 

  25. Smith A, Zeng W, Lucas S, Grogan B, Blackmarr A, Wo S, Peterson S, Gardai S (2021) Abstract 1583: SEA-TGT is an empowered anti-TIGIT antibody that displays superior combinatorial activity with several therapeutic agents. In: Immunology. Am Assoc Cancer Res 1583–1583

  26. Shirasuna K, Koelsch G, Seidel-Dugan C, et al (2021) Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody. Cancer Treat Res Commun 28:100433

Download references

Author information

Authors and Affiliations

  1. Salt Lake City, USA

    Vaia Florou & Ignacio Garrido-Laguna

Authors
  1. Vaia Florou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ignacio Garrido-Laguna
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

Dr. Vaia Florou has nothing to disclose. Dr. Ignacio Garrido-Laguna reports personal fees from Array BioPharma, and research funding (institutional) from Novartis, Ignyta, Halozyme, Bristol-Myers Squibb, Bayer, Pfizer, Newlink Genetics, MedImmune, Lilly, Incyte, GlaxoSmithKline, OncoMed, ARMO BioSciences, Glennmark.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Immuno-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Florou, V., Garrido-Laguna, I. Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer. Curr Oncol Rep 24, 1107–1112 (2022). https://doi.org/10.1007/s11912-022-01281-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-022-01281-5

Keywords

Search

Navigation